For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an increased risk for renal events.

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

INNOVATE Corp. surged 150% after its subsidiary MediBeacon received FDA approval for its TGFR system. See why I rate VATE ...

Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

In a remarkable display of market confidence, VATE stock has surged to a 52-week high, with shares trading at an impressive $13.31, representing a dramatic 309% increase from its 52-week low of $3.25.

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...